Medibank share price edges lower amid $31 million joint venture news

The Medibank joint venture with Aurora Healthcare aims to integrate inpatient and out-of-hospital care.

| More on:
A male investor wearing a white shirt and blue suit jacket sits at his desk looking at his laptop with his hands to his chin, waiting in anticipation.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The Medibank share price has dipped into the red
  • The ASX 200 health insurer has entered into a 50/50 joint venture with Aurora Healthcare, known as iMH
  • iMH will initially invest $31 million to establish three mental-health hospitals

The Medibank Private Ltd (ASX: MPL) share price has dipped into the red in early morning trade, down 0.3%.

Shares in the S&P/ASX 200 Index (ASX: XJO) financial services stock, Australia's biggest health insurer, closed yesterday trading for $3.26. Shares are currently swapping hands for $3.25.

This comes after more than $5.3 million worth of shares have already changed hands this morning following news of a $31 million joint venture.

What's happening with the joint venture?

The Medibank share price is edging lower amid news that the company has entered into a 50/50 joint venture with Aurora Healthcare, known as iMH, that will establish three mental-health hospitals.

iMH will initially invest $31 million into the three hospitals delivering 153 new mental health beds along with out-of-hospital support services like telehealth in home and community settings.

Aurora Healthcare is providing two hospitals in New South Wales and the Australian Capital Territory, Deakin Private Hospital and Hirondelle Private hospital. iMH will invest in a new 56-bed mental health facility. That will be developed in Alexandria, New South Wales.

The joint venture's acquisition of Deakin Private Hospital and Hirondelle Private hospital has been completed. The investment for the new facility in Alexandria is in the pipeline.

Executive commentary

Commenting on the development, Aurora Healthcare Australia CEO Julia Strickland-Bellamy, said:

The model will address the clear unmet demand in the community. In our network alone, the wait list for outpatient psychiatry has been at around six months over the past two years.

Providing people with treatment options beyond what has historically been solely hospital-centric care will help to support greater access, choice and flexibility.

Addressing the issue that the health insurer might influence a patient's decisions, Strickland-Bellamy said, "It's ultimately about the most appropriate treatment pathway for each individual patient, regardless of their private health insurer. All decisions about their suitability for the model will be made by the patient alongside their doctor and the hospital's clinical team."

Medibank group executive and CEO of Amplar Health Andrew Wilson said, "Integrating inpatient and out-of-hospital care helps patients access support when and where they need it."

Wilson added:

It shouldn't have to be one or the other. Many patients would benefit from the iMH model, which is designed around their individual needs and circumstances under the direction of their treating psychiatrist.

Deakin Private Hospital will open in the coming months, while Hirondelle Private Hospital is expected to open later this year.

Medibank share price snapshot

As you can see in the chart below, the Medibank share price has had a good run in 2023, up 10% since the closing bell on 30 December.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A doctor appears shocked as he looks through binoculars on a blue background.
Opinions

4DMedical shares crash 20% this week: Should investors cut their losses on the once-booming stock?

The shares are now down 6.61% for the year to date.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

Top broker tips 57% upside for beaten-down Telix shares

A leading broker expects a big rebound in Telix shares in 2026.

Read more »

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

Here's why Anteris shares are in a trading halt today

The company is undertaking a US$300m capital raising.

Read more »

Female scientist working in a laboratory.
Healthcare Shares

Telix shares in focus as the company meets guidance

More good news from the drug developer.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

What are the healthcare stocks where RBC Capital Markets thinks you can make money?

The top buys in the sector, listed.

Read more »

A sad looking scientist sitting and upset about a share price fall.
Healthcare Shares

Polynovo shares fall despite yesterday's upbeat update. Here's what investors are watching

Polynovo shares slide after a solid update as investors wait for clearer growth signals.

Read more »

Woman flexes muscles after donating blood.
Healthcare Shares

Check out this CSL share price forecast for 2026. It's hard to believe!

RBC Capital Markets thinks CSL is a bargain at current levels.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Good news out of China has this drug company's shares higher

A major new market will open up following this approval.

Read more »